A2 Refereed review article in a scientific journal
Genetic biomarkers to guide poly (ADP-ribose) polymerase inhibitor precision treatment of prostate cancer
Authors: Varnai Reka, Sipeky Csilla
Publisher: FUTURE MEDICINE LTD
Publication year: 2020
Journal: Pharmacogenomics
Journal name in source: PHARMACOGENOMICS
Journal acronym: PHARMACOGENOMICS
Volume: 21
Issue: 15
First page : 1101
Last page: 1115
Number of pages: 15
ISSN: 1462-2416
eISSN: 1744-8042
DOI: https://doi.org/10.2217/pgs-2020-0019
Abstract
Precision therapy for a subgroup of genetically defined metastatic castration-resistant prostate cancer patients may become a reality in the near future. DNA damage repair gene mutated prostate cancer might be vulnerable to treatment with PARP inhibitors (PARPi). PARPi clinical trials for prostate cancer investigate both germline and somatic genomic alterations of 43 genes for the applicability as genomic biomarker of PARPi sensitivity. Clinical trials with preliminary results show that BRCA2 and BRCA1, but also ATM, additionally BRIP1, FANCA, CDK12 and PALB2 may affect clinical end points, and may be potential candidates for genome guided patient selection in PARP inhibitor treatment of prostate cancer.
Precision therapy for a subgroup of genetically defined metastatic castration-resistant prostate cancer patients may become a reality in the near future. DNA damage repair gene mutated prostate cancer might be vulnerable to treatment with PARP inhibitors (PARPi). PARPi clinical trials for prostate cancer investigate both germline and somatic genomic alterations of 43 genes for the applicability as genomic biomarker of PARPi sensitivity. Clinical trials with preliminary results show that BRCA2 and BRCA1, but also ATM, additionally BRIP1, FANCA, CDK12 and PALB2 may affect clinical end points, and may be potential candidates for genome guided patient selection in PARP inhibitor treatment of prostate cancer.
UTU Research Portal